[Direct answer]In the Beijing area, if patients are harmed while participating in clinical trials of drugs or medical devices, the sponsors, clinical trial institutions (hospitals), and researchers shall bear legal responsibility according to the law. According to the Civil Code and the Good Clinical Practice (GCP), the safety and rights of subjects are strictly protected. If harm results from violations of the protocol, operational errors, defects in informed consent, failure to handle adverse events in a timely manner, or failure to fulfill the obligation to inform of risks, the responsible parties shall compensate for the harm. Patients can claim medical expenses, loss of income, disability compensation, and emotional distress. It is recommended to seal the research materials, preserve the informed consent forms and medical records, and consult professional lawyers in a timely manner. For more details, please refer to the following link:Personal injury and medical dispute services.

I. Problem background and typical scenarios

Clinical trial accidents often occur in the trials of new drugs for tumors and rare diseases, or in the validation of medical devices. Typical cases include: subjects not receiving timely treatment after experiencing serious adverse events; trial protocols being modified without authorization and used beyond the approved indications; informed consent forms failing to fully disclose risks; control group designs causing patients to miss out on standard treatment; and data fraud concealing harm. Many patients mistakenly believe that they "bear the consequences themselves" because they "voluntarily signed the consent form", or are too afraid to seek justice due to information asymmetry. In fact, the consent form does not exempt institutions from their statutory protection obligations, and those at fault must still be held accountable. In cases involving medical disputes, relevant provisions of the Medical Disputes Resolution Law can be referenced.Personal injury and medical dispute servicesEvaluation.

II. Key points of contention

There are three main points of contention. Firstly, the determination of fault: whether the plan complies with regulations, whether the adverse events are handled in a timely manner, and whether the information is fully disclosed are prerequisites for assigning responsibility. Secondly, the causality: whether the damage is caused by the experimental intervention rather than the disease itself, often requiring professional appraisal. Thirdly, the subject of responsibility: the division of responsibilities and the joint and several liability among the sponsor (pharmaceutical company), the research institution (hospital), and the individual researchers. For cases involving institutional responsibility, reference can be made to the relevant provisions of the Pharmaceutical GMP.Special services and other case servicesClarify the main subject.

III. Professional analysis by Henglue Law Firm

Based on our practical observations in handling medical malpractice and clinical trial disputes, the most critical and challenging aspect of such cases is the "asymmetry of evidence" — the research protocols, original records, and ethical review documents are typically held by the sponsors and institutions. According to Article 121 of the Civil Code, if a patient suffers harm during the medical treatment process and the medical institution or its medical staff are at fault, the medical institution shall compensate the patient; the GCP explicitly requires sponsors to establish mechanisms for adverse reaction monitoring and compensation. Henglue Lawyers typically recommend the following actions: immediately copy and seal the medical records and informed consent forms, file complaints with the ethics committee and regulatory authorities (the National Medical Products Administration and the National Health Commission), apply for a medical malpractice appraisal, and be vigilant against institutions evading responsibility by claiming that "the trial risks have been disclosed." For cases involving multiple parties seeking compensation, follow-up legal actions can be initiated.Creditor-debtor relations and enforcement case services.

IV. Practical suggestions and legal basis

The legal basis is Article 121 of the Civil Code (implemented on January 1, 2021) (Liability for Medical Damage), Article 1179 (Scope of Compensation); the Drug Administration Law (amended on August 26, 2019) regarding the protection of subjects; the Quality Management Guidelines for Clinical Trials of Drugs (implemented on July 1, 2020) regarding informed consent, handling of adverse events, and the sponsor's obligation to compensate; and the Regulations on the Prevention and Handling of Medical Disputes (implemented on October 1, 2018). For subjects seeking to protect their rights, they can refer to the above-mentioned provisions.Special services and other case-related servicesFollow the proper procedures. Practical advice: Before signing the consent form, carefully review all the potential risks and keep a record of the discussions; immediately seal off the research materials and medical records if an incident occurs; file a complaint with the ethics committee, the drug regulatory authority, and the health department; apply for a medical damage appraisal to clarify the fault and causality; if mediation fails and you decide to sue the sponsor and the institution, claim compensation for medical expenses, disability, and psychological damage.

5. Henglue Law Firm's Advice

The "signature consent" of clinical trial subjects does not mean they are waiving their right to claim compensation. The first step is to seal the informed consent form, medical records, and research protocols to prevent the data from being modified; the second step is to provide timely treatment and fully document the course of adverse events; the third step is to file a complaint with the ethics committee and regulatory authorities to apply external pressure; and the fourth step is to apply for a medical damage appraisal to identify the fault of the institution or the sponsor. Do not be dissuaded by the argument that "there are inherent risks in the trial", as the statutory obligation to provide protection exists independently. If you need to determine the responsible parties and the scope of compensation, you can seek assistance fromSpecial services and other case servicesHelp.

VI. Frequently Asked Questions

Q1: If I sign the informed consent form, can I still claim compensation if an accident occurs during the experiment?

Yes. The informed consent form is designed to inform the risks, but it does not exempt the institution and the sponsor from their legal obligations to protect participants. According to Article 121 of the Civil Code and GCP, if there are violations of the trial protocol, operational errors, untimely handling of adverse events, or insufficient disclosure of information in the trial, and the harm is causally related to the trial, the subjects may claim compensation. The consent form only proves that you are aware of the risks and cannot be used as a get-out-of-jail-free card. It is recommended to keep the consent form and research materials, and claim compensation after proving that the institution is at fault. If necessary, a lawyer can assess the proportion of fault.

Q2: What evidence do I need to prepare?

The core evidence includes: informed consent forms (to prove that the informed consent content was disclosed and the signatory's identity), research protocols and ethics review documents, complete medical records and examination reports (to prove the damage and adverse events), medical consultation and emergency treatment records, communication records with researchers, and materials provided by the sponsor. The evidence is organized around the "compliance obligations - institutional faults - damage consequences - causality". Most of the research materials are held by the institution, and the court can be applied to retrieve or preserve the evidence to prevent it from being tampered with; when necessary, a medical malpractice appraisal can be commissioned to restore the faults.

Q3: How much does it cost to sue the applicant and the hospital?

The litigation fees shall be calculated in accordance with the "Measures for the Payment of Litigation Fees", based on the amount of the litigation request and accumulated in stages. The losing party shall bear the fees. Such cases involve medical treatment, disability, follow-up treatment, and mental damage, with higher claim amounts. The attorney's fees shall be negotiated based on the complexity of the case and the subject matter, and the specific amount shall be subject to the entrustment contract. It is recommended to calculate the total amount of compensation that can be claimed before suing and compare it with the litigation fees and attorney's fees. For drug companies' applicants, their compensation capacity is usually strong, and they can be listed as co-defendants in priority to enhance the possibility of enforcement.

Q4: How long does it typically take to reach a conclusion on a claim for damages from a clinical trial?

Complaints to the ethics committee, drug regulatory authorities, or health departments may take several weeks to months to receive a response; medical damage appraisals themselves often require several months. First-instance litigation is typically concluded within six months under ordinary procedures and three months under summary procedures, but cases requiring appraisals will be significantly delayed. If an appeal is filed, the second-instance litigation generally takes three months. Overall, such highly specialized and evidence-intensive cases often take about a year from negotiation to recovery of funds. It is recommended to apply for evidence preservation and data sealing during litigation, and to apply for preliminary enforcement or property preservation as needed.

Q5: If an accident happens to me as a subject, what should I do first?

First step: Immediately stop the trial-related interventions and seek treatment at a regular hospital, fully documenting the course of the adverse event; Second step: Copy and seal the informed consent forms, medical records, research protocols, and ethics review documents to prevent the information from being modified or lost; Third step: Submit a complaint to the trial institution's ethics committee and the drug regulatory and health authorities to report the situation; Fourth step: Apply for a medical injury appraisal to determine the fault and causality; Fifth step: Present the evidence and negotiate with the sponsor and the institution. If no resolution is reached, file a lawsuit to jointly claim compensation. Maintain communication records throughout the process and, if necessary, engage a professional lawyer to assist.

The above content is based on the judicial practice in the Beijing area. The facts of individual cases and the jurisdiction of the court may affect the conclusions. Welcome to consult Henglue Lawyers for specific situations.

If you are facing similar problems, it is recommended that you consult a professional lawyer as soon as possible with the evidence materials, so as to avoid missing the statutory time limit. →Personal injury legal services·Beijing Henglu Law Firm

Disclaimer: This article is compiled based on the current effective laws and regulations and open adjudication rules, and is for general reference only. It does not constitute a formal legal opinion on specific cases. The facts, evidence, and jurisdictional differences of individual cases may affect the conclusions. If you encounter disputes, please consult a practicing lawyer in time.